

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Nai-Kong, CHEUNG

U.S. Serial No.: Not Yet Known, continuation-in-part of International Application No. PCT/US02/01276, filed January 15, 2002, which claims benefit of U.S Serial No. 60/261,911, filed on January 16, 2001

Filed : Herewith

For : THERAPY-ENHANCING GLUCAN

Law Offices of Albert Wai-Kit Chan, LLC  
World Plaza, Suite 604  
141-07 20<sup>th</sup> Avenue  
Whitestone, New York 11357

July 16, 2003

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir/Madam:

INFORMATION DISCLOSURE STATEMENT

In accordance with his duty of disclosure under 37 C.F.R. §1.56, Applicant would like to direct the Examiner's attention to the following references which are listed below and on Form PTO/SB/08A and PTOSB/08B (which is attached hereto as **Exhibit A**), and each individual reference further attached as **Exhibit 1** through 7.

1. PCT International Search Report, June 5, 2002, for CHEUNG, Nai-Kong, PCT/US02/01276, "THERAPY-ENHACING GLUCAN." **[Exhibit 1]**
2. U.S PCT International Preliminary Examination Report, March 27, 2003, for CHEUNG, Nai-Kong, PCT/US02/01276, "THERAPY-ENHACING GLUCAN." **[Exhibit 2]**
3. U.S. Patent 3,987,166, October 19, 1976, Komatsu et al., October 19, 1976 "Treatment of Tumors with Glucan Composition in Mice and Rats." **[Exhibit 3]**

Applicant : Nai-Kong CHEUNG  
U.S. Serial No.: Not Yet Known  
Filed : Herewith  
Page : 2

4. U.S. Patent 5,622,939, April 22, 1997, James et al.,  
"Glucan Preparation." [Exhibit 4]

5. U.S. Patent No. 5,980,918, November 9, 1999, Barbara K.  
Klein, "β-D-Glucan Topical Composition." [Exhibit 5]

6. U.S. Patent No. 5,189,028, February 23, 1993, Nikl et  
al., "Composition and Method to Enhance the Efficiency  
of a Fish Vaccine and to Stimulate the Immune System of  
Fish." [Exhibit 6]

7. U.S. Patent No 4,833,131, May 23, 2003, Williams et  
al., "Soluble Phosphorylated Glucan: Methods and  
Compositions for Wound Healing." [Exhibit 7]

If a telephone interview would be of assistance in advancing  
prosecution of the subject application, Applicant's undersigned  
attorney invites the Examiner to telephone him at the number  
provided below.

No fee is deemed necessary in connection with this Information  
Disclosure Statement. However, if any additional fee is required,  
authorization is hereby given to charge the amount of any such fee  
to Deposit Account No. 50-1891.

Respectfully submitted,

Albert Wai-Kit Chan

Albert Wai-Kit Chan  
Registration No. 36,479  
Attorney for Applicant(s)  
Law Offices of  
Albert Wai-Kit Chan, LLC  
World Plaza, Suite 604  
141-07 20<sup>th</sup> Avenue  
Whitestone, New York 11357  
Tel: (718) 357-8836  
Fax: (718) 357-8615  
e-mail: kitchanlaw@aol.com

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>		Application Number	Not Yet Known
		Filing Date	July 16, 2003
		First Named Inventor	Nai-Kong, CHEUNG
		Art Unit	
		Examiner Name	
Sheet	1	of	1
		Attorney Docket Number	639-B-PCT-US

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.<sup>2</sup> Applicant's unique citation designation number (optional).<sup>3</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.4. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).<sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.<sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: **Commissioner for Patents, Washington, DC 20231.**

*If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.*

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

2

of

2

**Complete if Known**

Application Number	Not Yet Known
Filing Date	July 16, 2003
First Named Inventor	Nai-Kong CHEUNG
Art Unit	
Examiner Name	

Attorney Docket Number

639-B-PCT-US

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
1		PCT International Search Report, June 5, 2002, for CHEUNG, Nai-Kong, PCT/US02/01276, "THERAPY-ENHANCING GLUCAN."	
2		PCT International Preliminary Examination Report, March 27, 2003, for CHEUNG, Nai-Kong, PCT/US02/01276, "THERAPY-ENHANCING GLUCAN."	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.